|
市場調查報告書
黑素瘤(melanoma)，細胞凋亡，血管新生:藥物開發策略分析
Triple Analysis: Melanoma, Apoptosis and Angiogenesis
|
黑素瘤(melanoma)，細胞凋亡，血管新生:藥物開發策略分析 是由出版商BioSeeker Group AB在2012年01月所出版的。
這份英文市場調查報告書包含4098 Pages 價格從美金5175起跳。
本報告以黑素瘤(melanoma)的藥物開發策略和細胞凋亡及血管新生的機制、目標、影響領域為焦點，彙整各種的藥劑目標策略，化合物策略競爭基準，開發平台及最佳投資組合計劃等資料，為您概述為以下內容。
第1章 黑素瘤(melanoma)
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:各開發階段的黑色素瘤(Melanoma)藥劑目標策略
- 使用中的化合物策略:各化合物策略競爭基準
- 開發平台及最佳投資組合:黑色素瘤(Melanoma)治療藥物開發平台的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
- 圖表
第2章 細胞凋亡
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:細胞凋亡治療開發平台上指定的藥劑目標是否成熟，是否有特色，臨床評估如何
- 使用中的化合物策略:細胞凋亡藥物的各類型化合物的競爭基準
- 細胞凋亡的癌適應症症狀選擇
- 最佳投資組合計劃:細胞凋亡開發平台的競爭基準
- 藥品目錄
- 企業目錄
- 圖表
第3章 血管新生
- 本報告的範圍
- 為達成最高治療效果及投資報酬率的治療目標檢討
- 新藥的上市:影響血管新生的癌治療藥目標策略
- 使用中的化合物策略:影響血管新生各化合物策略的治療樂物競爭基準
- 影響藥品作用的血管新生的癌症症狀
- 開發平台和最佳投資組合計劃:影響癌症治療藥開發平台血管新生的競爭基準
- 免責聲明
- 藥品目錄
- 企業目錄
Abstract
Description
This triple analysis focuses on cancer drug development strategies in Melanoma
and by the two mechanism/target/effect areas of Apoptosis and Angiogenesis.
Each of these three individual parts is evaluated according to standardized
criteria in a five pillar pipeline drug assessment methodology to compare drug
development strategies in oncology. This makes it easy to find and compare
analysis not only within one single cancer focus area but also between
different areas.
Below is a short synopsis of each part included in this report:
Part I: Melanoma
- The melanoma report part comprises defined and up to date development
strategies for 218 melanoma drugs within the portfolio of 138 investigators,
from Ceased to Marketed. This part extensively analyses their 170 identified
drug targets, organized into 151 drug target strategies, and assesses them in
eight different compound strategies in melanoma.
Part II: Apoptosis
- The apoptotic cancer drug report part comprises defined and up to date
development strategies for 234 drugs in oncology within the portfolio of 158
companies world-wide, from Ceased to Marketed. The report extensively analyses
their 181 identified drug targets, organized into 157 drug target strategies,
and assesses them in 69 cancer indications.
Part III: Angiogenesis
- The angiogenesis report part comprises defined and up to date development
strategies for 239 drugs affecting angiogenesis in oncology within the
portfolio of 148 investigators, from Preclinical to Marketed. This report part
extensively analyses 174 identified targets of angiogenesis affecting drugs,
organized into 167 drug target strategies, and assesses them in 64 different
cancer indications.
The report is written for you to understand and assess the impact of
competitor entry and corresponding changes to development strategies for your
own portfolio products. It helps teams to maximize molecule value by selecting
optimal development plans and manage risk and uncertainty. The report serves
as an external commercial advocate for pharmaceutical companies' pipeline and
portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide
development of early product ideas and ensure efforts are aligned with
business objectives
- Assisting you to make informed decisions in selecting cancer indications
that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to
provide accurate data for valuation of pipeline, in-licensing and new business
opportunities
- Providing you with commercial analytic support for due diligence on
in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area
strategies
- Integrating knowledge for you to consider the therapeutic target for the
highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally
to PPP and to stakeholders across your own organization. The report will also
be an important part of creating and implementing a market development plan
for cancer drugs to insure that the optimal market conditions exist by the
time the products are commercialized.
Table of Contents
Key Topics Covered:
Part I: Melanoma
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target Among Melanoma Drugs for the Highest
Therapeutic Outcome and Return on Investment (170 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Melanoma Drugs by their Highest Stage of Development (151 Drug Target
Strategies and 218 Melanoma Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs
by Compound Strategy (8 Compound Strategies)
- 9. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Melanoma Drug Pipeline by Investigator (138 Companies)
- 10. Disclaimer
- 11. Drug Index
- 12. Company Index
- Figures: Includes 6 Figures
- Tables: Includes 196 Tables
- Total Number of Pages: 777
Part II: Apoptosis
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for
the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug
Target Strategies and 234 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Apoptotic
Cancer Drugs by Compound Strategy(7 Compound Strategies)
- 9. Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer
Indications)
- 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234
Drugs)
- Disclaimer
- 11. Drug Index
- 12. Company Index
- Figures: Includes 7 Figures
- Tables: Includes 315 Tables
- Total Number of Pages: 1,617
Part III: Angiogenesis
- 5.1. The Scope of this Report
- 6. Consider the Therapeutic Target for the Highest Therapeutic Outcome and
Return on Investment (174 Drug Targets)
- 7. Emerging New Products to Established Ones: Drug Target Strategies of
Cancer Drugs Affecting Angiogenesis by their Highest Stage of Development (167
Drug Target Strategies and 239 Drugs)
- 8. Compound Strategies at Work: Competitive Benchmarking of Cancer Drugs
Affecting Angiogenesis by Compound Strategy (7 Different Compound Strategies)
- 9. Selecting Cancer Indications for Angiogenesis Affecting Drugs in
Oncology (64 Cancer Indications)
- 10. Pipeline and Portfolio Planning: Competitive Benchmarking of the
Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (148
Investigators)
- 10. Disclaimer
- 11. Drug Index
- 12. Company Index
- Figures: Includes 7 Figures
- Tables: Includes 300 Tables
- Total Number of Pages: 1227
This Report Includes the Following Companies:
- 3SBio
- Abbott
- Abiogen
- Abraxis BioScience
- Acceleron Pharma
- Access
- ACT Biotech
- Actelion
- Active Biotech
- Adherex
- Advanced Cancer Therapeutics
- Advanced Life Sciences
- Advantagene
- Advaxis
- Advenchen
- AEgera
- AEterna Zentaris
- Agennix
- Aida Pharmaceuticals
- Aileron Therapeutics
- Alnylam
- Altor BioScience
- Ambit Biosciences
- Ambrilia Biopharma
- Amgen
- Amphora
- Anadys Pharmaceuticals
- Anaphore
- Anavex Life Sciences
- AngioChem
- Angiogen
- Angiogenex
- Angstrom Pharmaceuticals
- Ansaris
- Antisense Pharma
- Antisoma
- Aphios
- Apogenix
- ApopLogic Pharmaceuticals
- Apotex
- Arana Therapeutics
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Ascenta Therapeutics
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- Austrianova
- Avila Therapeutics
- Basilea Pharmaceutica
- Bayer
- Bio-Medisinsk Innovasjon
- BioAlliance Pharma
- BioAxone
- Biocad
- Biocompatibles
- Biogen Idec
- BioInvent
- Biokine Therapeutics
- BioLineRx
- Biomas
- Bionovo
- BioNumerik
- Biosceptre
- Biotecnol
- BioVex
- Boehringer Ingelheim
- Bolder BioTechnology
- Bristol-Myers Squibb
- Cancer Research Technology
- CDG Therapeutics
- Celecure
- Celera
- Celgene
- Cell Genesys
- Cell Therapeutics
- CellCeutix
- Celldex Therapeutics
- Cellmid
- Celtic Pharma
- Cephalon
- ChemoCentryx
- Chemokine Therapeutics
- China Sky One Medical
- Chlorogen
- Choongwae
- Chroma Therapeutics
- Circadian Technologies
- CJ Corp
- Clavis Pharma
- Cleveland BioLabs
- CombinatoRx
- Coronado Biosciences
- Cosmo Pharmaceuticals
- Critical Outcome Technologies
- CSL
- Cue Biotech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- Cynvec
- CytImmune Sciences
- Cytochroma
- Cytokinetics
- CytRx
- Daewoong
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dara Biosciences
- Deciphera Pharmaceuticals
- Dendreon
- DeveloGen
- DNAVEC
- Dong-A
- Dyax
- Eisai
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Endocyte
- EntreMed
- Enzon
- EpiCept
- Erimos
- Exelixis
- ExonHit Therapeutics
- Facet Biotech
- Five Prime Therapeutics
- Flamel Technologies
- GammaCan
- Genmab
- Genta
- GenVec
- Genzyme
- Gerolymatos
- Geron
- GlaxoSmithKline
- GlycoGenesys
- Glycotope
- GPC Biotech
- Green Cross
- Harbor BioSciences
- Hemispherx Biopharma
- Hoffmann-La Roche
- Human Genome Sciences
- Hy BioPharma
- Ichor Medical Systems
- Idera Pharmaceuticals
- ImClone Systems
- Immunocore
- ImmunoGen
- ImmuPharma
- Immutep
- Infinity Pharmaceuticals
- Innate Pharma
- InNexus Biotechnology
- Inotek
- Inovio
- Insmed
- Insys Therapeutics
- Intradigm
- Intrexon
- Introgen Therapeutics
- Ipsen
- Isis Pharmaceuticals
- ISU ABXIS
- Jennerex Biotherapeutics
- Johnson & Johnson
- KAI Pharmaceuticals
- Kalypsys
- Karus Therapeutics
- Karyon-CTT
- Keryx Biopharmaceuticals
- Kiadis
- Kirin Pharma
- Kringle Pharma
- Kyowa Hakko Kirin
- Lee's Pharmaceutical
- Leo
- LG Life Sciences
- Ligand
- Lorus Therapeutics
- Mannkind
- MAT Biopharma
- MediGene
- Medisyn Technologies
- Merck & Co
- Merck KGaA
- Mersana Therapeutics
- MethylGene
- Micromet
- Mitsubishi Tanabe Pharma
- Mochida
- Mojave Therapeutics
- MolMed
- Mologen
- Morvus Technology
- Nereus Pharmaceuticals
- Nerviano Medical Sciences
- NewSouth Innovations
- NIH
- Nippon Shinyaku
- Non-industrial source
- Novacea
- NovaLead
- Novartis
- Novelix
- Novogen
- Oasmia
- Oncalis
- Onconova
- OncoTherapy Science
- Oncothyreon
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- PanaGin
- Patrys
- PBL Therapeutics
- Pepscan Therapeutics
- PepTx
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacopeia
- Pharmacyclics
- PharmaMar
- Pharminox
- Philogen
- PhiloGene
- Pierre Fabre
- Piramal
- Plexxikon
- Progen
- ProMetic Life Sciences
- Protein Sciences
- PTC Therapeutics
- QLT
- Reata Pharmaceuticals
- Receptor BioLogix
- Regeneron
- Regulon
- Rexahn
- Rigel
- Rosetta Genomics
- Sanofi
- Sanofi-Aventis
- Santaris Pharma
- Sareum
- SBI Biotech
- Scancell
- SciClone Pharmaceuticals
- Seattle Genetics
- Semafore Pharmaceuticals
- Senesco Technologies
- Shire
- Sigma-Tau
- Simcere Pharmaceuticals
- Solbec Pharmaceuticals
- Spear Therapeutics
- Spirogen
- SRI International
- SuperGen
- Swedish Orphan Biovitrum
- Switch Pharma
- SymBio Pharmaceuticals
- Symbiotec
- SynDevRx
- Takeda
- Targa Therapeutics
- Targepeutics
- Tau Therapeutics
- Taxolog
- Telik
- TetraLogic Pharmaceuticals
- Teva
- Thallion Pharmaceuticals
- Therion Biologics
- ThromboGenics
- Tigris Pharmaceuticals
- ToolGen
- TopoTarget
- Tracon Pharmaceuticals
- Transgene
- UCB
- UMN Pharma
- ValiRx
- VaxOnco
- VBL Therapeutics
- Vectura
- Velacor Therapeutics
- Vertex Pharmaceuticals
- Vical
- Wilex
- VioQuest
- Viragen
- Viralytics
- ViroTarg
- VM Discovery
- Wyeth
- Xerion
- York Pharma
- ZymoGenetics
A Shortlist of Drugs Included are:
- 131I-tositumomab
- AEG-35156
- aflibercept
- AG-14699
- agatolimod
- aldesleukin
- ALT-801
- alvocidib
- AME-133
- apatinib
- APG-101
- APO-866
- ARQ-197
- AS-101
- AS-1411
- astuprotimut-r
- axitinib
- bardoxolone methyl
- belinostat
- bevacizumab
- BIBF-1120
- BMS-663513
- bortezomib
- bosentan
- bosutinib
- brivanib alaninate
- BZL-101
- canfosfamide hydrochloride
- cediranib
- cenersen
- cilengitide
- cintredekin besudotox
- conatumumab
- cositecan
- crolibulin
- dasatinib
- decitabine
- denenicokin
- dinaciclib
- dovitinib lactate
- dulanermin
- EMD-273063
- endostatin
- entinostat
- enzastaurin hydrochloride
- epirubicin
- everolimus
- Exherin
- fosbretabulin tromethamine
- fresolimumab
- gataparsen
- gefitinib
- glembatumumab
- golnerminogene pradenovec
- GT-111
- GV-1001
- HBP-347
- HE-3235
- histamine dihydrochloride
- ibritumomab tiuxetan
- idronoxil
- imatinib mesilate
- imetelstat
- IMP-321
- INGN-241
- interferon-alpha
- interferon-alpha2
- interferon-alpha2a
- interferon-alpha2b
- interferon-beta
- interleukin-2, 2nd-generation
- intetumumab
- IPH-1101
- ipilimumab
- ispinesib mesylate
- JX-594
- kahalalide F
- L19-IL2
- lestaurtinib
- linifanib
- LipoVIL12
- litronesib
- lonaprisan
- lumiliximab
- mapatumumab
- MDX-1106
- MetXia
- MGN-1601
- midostaurin
- MKC-1
- MKC-1106-MT
- mocetinostat
- motesanib diphosphate
- motexafin gadolinium
- navitoclax
- noscapine
- obinutuzumab
- oblimersen sodium
- ON-01910
- Oncohist
- OncoVEX GM-CSF
- OTS-102
- P-276-00
- panobinostat
- PAT-SC1
- patupilone
- pazopanib hydrochloride
- PBI-1402
- PCI-24781
- peginterferon alfa-2b
- perifosine
- plitidepsin
- PLX-4032
- PX-12
- quarfloxacin
- quinacrine
- R-(-)-gossypol
- RAF-265
- ramucirumab
- retaspimycin
- ridaforolimus
- sagopilone
- sargramostim
- seliciclib
- selumetinib
- sodium stibogluconate
- sorafenib tosylate
- SPC-2996
- s-lapachone
- SU-6668
- sunitinib malate
- talactoferrin alfa
- terameprocol
- thymalfasin
- tigapotide triflutate
- tigatuzumab
- tipifarnib
- TL-32711
- topotecan
- trabedersen
- tremelimumab
- triciribine phosphate
- TRU-016
- vandetanib
- velimogene aliplasmid
- veliparib
- volasertib
- volociximab
- vosaroxin
- XL-147
- XL-184
- XL-647
- YM-155
|
